Intrinsiqq
10x Genomics Inc. logo

10x Genomics Inc.

TXG

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$7.75B
EPS-$0.52
P/E-114.00
P/FCF82.69
EV/EBITDA-100.48
FCF Yield1.2%
Div. Yield–
Net Debt/FCF-5.3x
10x Genomics Inc. intrinsic value
52-Week Range
$15.46$97.74

Profitability & Returns

Revenue (TTM)

$619M

▲ +5.2% YoY

Net Income (TTM)

-$67M

▲ +76.2% YoY

Op. Margin

-11.67%

▲ +22.4pp YoY

ROIC

-6.35%

▲ +13.1pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

$94M

▲ +2371.2% YoY

Op. Cash Flow (TTM)

$100M

▲ +1941.6% YoY

Net Debt

-$500M

Net Cash Position

Cash & Equiv.

$576M

5Y CAGR: +16.6%

Continue Research

Peers

Laboratory Analytical Instruments · Pick stocks to compare with TXG

CompareIntrinsic value
CTKBCytek Biosciences, Inc.
$5.83+7.96%50
PACBPacific Biosciences of California, Inc.
$2.26-7.00%26
QTRXQuanterix Corporation
$2.90+4.89%24
HBIOHarvard Bioscience, Inc.
$8.36-1.18%15
BIOBio-Rad Laboratories Inc.
$381.57+3.41%50
RVTYRevvity Inc.
$155.11+2.84%20
BRKRBruker Corporation
$61.31+5.60%35
MTDMettler-Toledo International Inc.
$1,722.15+2.57%41

Held by ETFs

TXG is in 87 US ETFs. The largest of them, with TXG's weight in each:

10x Genomics (TXG) in four numbers

Fair value (revenue)
$27.54
Price $59.28 is 115% above it.
Intrinsic Value
Quality score
48/100
Best check: margin trend, +20.8pp. Weakest: return on capital, -6.3%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-114.00
Negative: a loss over the last twelve months. Price to free cash flow 82.69.
Financials

Questions about 10x Genomics

Is 10x Genomics (TXG) overvalued?

At $59.28, 10x Genomics' price is 115% above the $27.54 a share fair value that Intrinsiqq's calculator gets from its revenue. It trades at 82.69 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is 10x Genomics' fair value?

Intrinsiqq's calculator puts 10x Genomics' fair value at $27.54 a share. It grows revenue per share 4.3% a year for 5 years, applies an exit P/S of 7.6, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $20.66. Every input can be changed on the Intrinsic Value tab.

Is 10x Genomics a high-quality business?

10x Genomics scores 48 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is margin trend at +20.8pp, and its weakest is return on capital at -6.3%. The Quality tab shows every check against its target.

Does 10x Genomics (TXG) pay a dividend?

No. 10x Genomics (TXG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in TXG's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing TXG

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.